Xeris Biopharma Holdings Inc
F:2B30
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Xeris Biopharma Holdings Inc
F:2B30
|
US |
|
K
|
Kingspan Group PLC
ISEQ:KRX
|
IE |
|
Great Southern Bancorp Inc
NASDAQ:GSBC
|
US |
|
Mediwelcome Healthcare Management & Technology Inc
HKEX:2159
|
CN |
|
OMV AG
F:OMV
|
AT |
|
SoftBank Group Corp
TSE:9984
|
JP |
|
Virbac SA
PAR:VIRP
|
FR |
|
E
|
Espey MFG and Electronics Corp
AMEX:ESP
|
US |
|
F
|
Finning International Inc
OTC:FINGF
|
CA |
|
F
|
Faurecia SE
XBER:FAU
|
FR |
|
T
|
Trident Ltd
NSE:TRIDENT
|
IN |
|
Iberdrola SA
MAD:IBE
|
ES |
|
Hyatt Hotels Corp
NYSE:H
|
US |
|
Fielmann AG
OTC:FLMNY
|
DE |
|
M
|
Mondi PLC
JSE:MNP
|
UK |
|
Marriott Vacations Worldwide Corp
NYSE:VAC
|
US |
|
WT Microelectronics Co Ltd
TWSE:3036
|
TW |
|
P
|
Power Generation Joint Stock Corporation 3
VN:PGV
|
VN |
|
M
|
Medifast Inc
F:MDF
|
US |
|
G
|
Greenroc Mining PLC
F:3WF
|
UK |
|
M
|
Milestone Scientific Inc
AMEX:MLSS
|
US |
|
A
|
Aeroports de Paris SA
DUS:W7L
|
FR |
|
C
|
Compagnie De l'odet SE
XMUN:49F
|
FR |
|
B
|
Boosh Plant Based Brands Inc
CNSX:VEGI
|
CA |
Discount Rate
2B30 Cost of Equity
Discount Rate
2B30's Cost of Equity, calculated using the formula Risk-Free Rate + Beta x ERP, stands at 8.29%. The Beta, indicating the stock's volatility relative to the market, is 0.94, while the current Risk-Free Rate, based on government bond yields, is 4.37%, and the ERP, measuring the extra return over the risk-free rate required by investors, is 4.18%.
2B30 WACC
Discount Rate
2B30's Weighted Average Cost of Capital (WACC) is calculated as the weighted average of its cost of equity and cost of debt, adjusted for tax. The WACC stands at 8.86%. This includes the cost of equity at 8.29%, calculated as Risk-Free Rate + Beta x ERP, and the cost of debt at 12.24%, reflecting the interest rate on 2B30's debt adjusted for tax benefits. The weight of debt in the capital structure is 14.34%.
What is 2B30's discount rate?
2B30's current Cost of Equity is 8.29%, while its WACC stands at 8.86%. The selection of the appropriate discount rate is contingent on the type of cash flows being discounted.
For Equity Valuation: When valuing equity, especially in scenarios where you are discounting cash flows to equity holders (such as Net Income, Earnings Per Share (EPS), or Free Cash Flow to Equity), the Cost of Equity should be used.
For Firm Valuation: In contrast, when valuing the entire firm and discounting cash flows available to both debt and equity holders (like Free Cash Flow to the Firm), the Weighted Average Cost of Capital (WACC) is the appropriate rate.
How is Cost of Equity for 2B30 calculated?
The Cost of Equity represents the return a company must offer investors to compensate for the risk of investing in its stock. It's calculated using the Capital Asset Pricing Model (CAPM), which combines the risk-free rate, the stock's beta, and the equity risk premium (ERP).
This model considers the inherent risk of investing in the stock compared to a risk-free investment and the market's overall risk.
Here is how we calculate the cost of equity for
2B30
How is WACC for 2B30 calculated?
WACC, or Weighted Average Cost of Capital, is a calculation that reflects the average rate of return a company is expected to pay its security holders to finance its assets. It is a critical measure in financial analysis for valuing a company’s entire operations.
The WACC formula combines the costs of equity and debt, weighted by their respective proportions in the company's capital structure.
Here is how we calculate WACC for
2B30
